Entero Therapeutics Sets Virtual Annual Meeting for June 30

TL;DR

**GRDX is holding a virtual annual meeting on June 30th, so get your 16-digit control number ready to vote on whatever they're pushing.**

AI Summary

Entero Therapeutics, Inc. (GRDX) filed a Definitive Proxy Statement (DEF 14A) on June 4, 2025, for its upcoming virtual Annual Meeting of Stockholders on June 30, 2025, at 12:00 P.M. Eastern Time. The filing primarily outlines the procedural details for the virtual meeting, including how stockholders can attend, vote, and submit questions via www.virtualshareholdermeeting.com/ENTO2025 using a 16-digit control number. The company, formerly known as First Wave BioPharma, Inc. and AzurRx BioPharma, Inc., is a pharmaceutical preparations company based in Boca Raton, Florida. The DEF 14A references the availability of its 2023 Annual Report on Form 10-K, filed March 29, 2024, and its 2024 Annual Report on Form 10-K/A, filed April 9, 2025, for detailed financial information. This proxy statement itself does not contain specific revenue or net income figures, nor does it detail new business changes or strategic outlooks, focusing instead on the mechanics of the annual meeting. Risks are implicitly tied to the general operations of a pharmaceutical company, but no new specific risks are disclosed in this procedural filing.

Why It Matters

This DEF 14A filing is crucial for Entero Therapeutics investors as it details the logistics for the 2025 Annual Meeting, where key corporate governance decisions will be made. The shift to a virtual meeting format via www.virtualshareholdermeeting.com/ENTO2025 impacts how stockholders engage with management and exercise their voting rights. For employees and customers, the outcome of shareholder votes on proposals, though not detailed here, could influence future company direction and stability. In the competitive pharmaceutical sector, transparent and accessible shareholder meetings are vital for maintaining investor confidence and corporate accountability.

Risk Assessment

Risk Level: low — The risk level is low because this DEF 14A filing is a procedural document outlining the logistics for an annual meeting, not disclosing new financial results, strategic shifts, or significant operational risks. It primarily informs stockholders about the virtual meeting on June 30, 2025, and how to participate, which carries minimal inherent risk.

Analyst Insight

Investors should review the 2023 Annual Report (filed March 29, 2024) and 2024 Annual Report (filed April 9, 2025) referenced in this filing to understand Entero Therapeutics' financial health and performance. Ensure you have your 16-digit control number to participate and vote at the virtual Annual Meeting on June 30, 2025, at 12:00 P.M. Eastern Time.

Key Numbers

• 2025-06-04 — Filing Date (Date the DEF 14A was filed with the SEC)
• 2025-06-30 — Annual Meeting Date (Date of Entero Therapeutics' 2025 Annual Meeting of Stockholders)
• 12:00 P.M. Eastern Time — Annual Meeting Time (Scheduled start time for the virtual Annual Meeting)
• 16 — Control Number Digits (Number of digits required for online participation in the virtual meeting)
• 2023 — Annual Report Year (Year for which the 10-K was filed on March 29, 2024)
• 2024 — Annual Report Year (Year for which the 10-K/A was filed on April 9, 2025)

Key Players & Entities

• Entero Therapeutics, Inc. (company) — Registrant and filer of DEF 14A
• First Wave BioPharma, Inc. (company) — Former name of Entero Therapeutics, Inc. until 20210921
• AzurRx BioPharma, Inc. (company) — Former name of Entero Therapeutics, Inc. until 20141103
• SEC (regulator) — Securities and Exchange Commission, where the filing was made
• Board of Directors (person) — Inviting stockholders to the Annual Meeting
• management (person) — Inviting stockholders to the Annual Meeting
• Delaware (company) — State of incorporation for Entero Therapeutics, Inc.
• Boca Raton, Florida (company) — Business address of Entero Therapeutics, Inc.
• June 30, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
• March 29, 2024 (date) — Filing date of the 2023 Annual Report on Form 10-K

FAQ

Industry Context

Entero Therapeutics operates within the pharmaceutical preparations sector, a highly competitive and innovation-driven industry. Companies in this space focus on research, development, and commercialization of new drug therapies. Key trends include advancements in biotechnology, increasing regulatory scrutiny, and the ongoing pursuit of treatments for unmet medical needs.

Regulatory Implications

As a pharmaceutical company, Entero Therapeutics is subject to stringent regulations from bodies like the FDA. Compliance with these regulations is critical for drug development, approval, and marketing. Any failure to adhere to these standards can lead to significant delays, fines, or product withdrawal, impacting financial performance and market access.

What Investors Should Do

1. Review the 2023 and 2024 Annual Reports (10-K and 10-K/A) for detailed financial performance and business operations.
2. Note the virtual format of the June 30, 2025 Annual Meeting and ensure you have your 16-digit control number for participation.

Key Dates

• 2025-06-04: Filing of Definitive Proxy Statement (DEF 14A) — Provides shareholders with information regarding the upcoming annual meeting and voting procedures.
• 2025-06-30: Annual Meeting of Stockholders — The date for shareholders to vote on company matters and hear updates, held virtually.
• 2024-03-29: Filing of 2023 Annual Report on Form 10-K — Provides audited financial statements and business overview for the fiscal year 2023.
• 2025-04-09: Filing of 2024 Annual Report on Form 10-K/A — Provides amended financial information for the fiscal year 2024.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC, containing information about the annual meeting of shareholders. (This document is the primary filing for the company's annual meeting.)

Virtual Meeting

A shareholder meeting conducted entirely online, allowing remote participation. (This is the format for Entero Therapeutics' 2025 Annual Meeting, impacting accessibility for shareholders.)

Control Number

A unique identifier required for shareholders to access and vote at the virtual annual meeting. (Essential for shareholders to participate in the meeting and exercise their voting rights.)

Form 10-K

An annual report required by the SEC that provides a comprehensive summary of a company's financial performance. (The 2023 and 2024 10-K filings contain the detailed financial data referenced by the proxy statement.)

Form 10-K/A

An amended annual report filed with the SEC to correct or supplement information in a previously filed 10-K. (Indicates that the 2024 financial information has been updated or corrected since its initial filing.)

Year-Over-Year Comparison

This DEF 14A filing focuses on the procedural aspects of the 2025 Annual Meeting. It references the 2023 Form 10-K filed on March 29, 2024, and the 2024 Form 10-K/A filed on April 9, 2025. Unlike a typical annual report, this proxy statement does not provide comparative financial metrics or discuss changes in revenue or profitability directly, but rather directs shareholders to the previously filed annual reports for such information.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 4, 2025 by Board of Directors regarding Entero Therapeutics, Inc. (GRDX).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR